Immunocore Holdings (IMCR) Share-based Compensation (2021 - 2026)

Immunocore Holdings (IMCR) has reported Share-based Compensation for 6 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation fell 33.59% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.5 million (down 0.59% YoY) and the FY2025 annual result came in at $37.7 million, up 10.26% from the prior year.
• Share-based Compensation retreated to $6.3 million in Q1 2026 per IMCR's latest filing, from $8.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for IMCR reached as high as $10.0 million in Q2 2025 and fell as low as $6.3 million in Q1 2026.
• A 5-year average of $8.4 million and a median of $8.5 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation sank 43.38% — and 2025, when it soared 49.98%.
• Year by year, Share-based Compensation stood at $8.1 million in 2022, then retreated by 10.8% to $7.2 million in 2023, then climbed by 20.53% to $8.7 million in 2024, then fell by 3.78% to $8.3 million in 2025, then decreased by 24.43% to $6.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $6.3 million, $8.3 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.